Classys Nears 50,000 Devices Sold Globally as Full-Lineup Growth Accelerates
Expands global portfolio beyond HIFU and MRF to include MNRF, laser, and dermabrasion devices, strengthening its medium- to long-term growth foundation 1H26 Exports, excluding shipments to its Brazilian subsidiary, grew 29% year over year, underscoring continued growth across global markets SEOUL, South Korea, Aug. 25, 2026 /PRNewswire/ -- Classys Inc. (KOSDAQ: 214150), a global medical aesthetics company,...
ICP DAS-BMP Brings Advanced Medical TPU Portfolio to Medical Manufacturing Asia 2026
HSINCHU, Aug. 25, 2026 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), will exhibit at Medical Manufacturing Asia 2026, taking place September 9–11 at the Marina Bay Sands Expo & Convention Centre in Singapore (Booth 2U20). Exhibiting together with its manufacturing partner, Towards...
Thailand’s Elite Business Leaders Forge Lasting Legacies at Asia Pacific Enterprise Awards 2026
BANGKOK, Aug. 25, 2026 /PRNewswire/ -- Thailand's elite business leaders and outstanding enterprises have been recognized for forging lasting legacies of excellence, innovation, and resilience at the Asia Pacific Enterprise Awards (APEA) 2026 Thailand. Organized by Enterprise Asia, the prestigious awards ceremony was held on 21 August 2026 at Conrad Bangkok, Thailand, celebrating visionary leaders and organizations whose...
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
SHANGHAI and HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the Phase I ATTRACT study of our proprietary ATG-201, a...
Dimora Medical Introduces New Pricing for MegaSorb™ Dressings, Expanding Access to Professional-Grade Wound Care
NEW YORK, Aug. 25, 2026 /PRNewswire/ -- Dimora Medical, a continuous innovator in high-end medical care supplies, today announced price reductions across its entire MegaSorb™ wound dressing lineup—with select SKUs discounted by up to 29% to make advanced wound management solutions more accessible to a broader range of households. The move reflects the company's ongoing commitment to helping...
WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER basis (41.5% growth on a CER basis) Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 million. Gross profit margin was 37.0%, a 0.9 percentage points increase compared to 2025 1H Adjusted net profit attributable to owners of the Company increased by...
Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth
SUZHOU, China, Aug. 24, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its interim results for the six months ended June 30, 2026 (the "Reporting Period") on August 21, 2026. During the first half of 2026, the...
ImmunoForge Selected for the Ministry of SMEs and Startups’ ‘Global TIPS R&D’ Program… “Expansion of the LMT Platform”
Development of Leptin receptor-based technology and hybrid LNP platform Combining Blood-Brain Barrier penetration and a one-month sustained-release formulation in a single structure, with potential applications in CNS-targeted therapeutics Technology validated by winning first place in Novo Nordisk's Open Innovation contest… Accelerating global technology transfer SEOUL, South Korea, Aug. 24,...
INDONESIAN HEALTHCARE TRAVEL TO MALAYSIA HITS RECORD RM2.2 BILLION AS MHX RETURNS TO YOGYAKARTA
YOGYAKARTA, Indonesia, Aug. 24, 2026 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) once again strengthened Malaysia's presence in Indonesia through MHX Yogyakarta 2026, held from 20 to 23 August 2026 at the Grand Atrium, Pakuwon Mall Jogja. The four-day event came on the back of a record year for the Indonesian...
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales SEOUL, South Korea, Aug. 24, 2026 /PRNewswire/ -- Hanmi Pharm...
